MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
As part of an overall corporate update, Dr. DeMesa will highlight thefollowing:
Additionally, interim 4-week data expected in October from a Phase IIviral kinetics combination study of celgosivir in patients with chronic HCV(genotype 1) infection are delayed due to sample analysis not being completedat a contract research organization. Results will be reported when available,which is now anticipated to be in November.
MIGENIX is committed to advancing therapy, improving health, and enrichinglife by developing and commercializing drugs primarily in the area ofinfectious diseases. The Company's clinical programs include drug candidatesfor the treatment of chronic hepatitis C infections (Phase II andpreclinical), the prevention of catheter-related infections (Phase III) andthe treatment of dermatological diseases (Phase II). MIGENIX is headquarteredin Vancouver, British Columbia, Canada with US operations in San Diego,California. Additional information can be found at www.migenix.com.
This news release contains forward-looking statements within the meaningof the United States Private Securities Litigation Reform Act of 1995, andforward-looking information within the meaning of applicable securities lawsin Canada, (collectively referred to as "forward-looking statements").Statements, other than statements of historical fact, are forward-lookingstatements. By their nature, forward-looking statements involve numerousassumptions, known and unknown risks and uncertainties, both general andspecific, that contribute to the possibility that the predictions, forecasts,projections and other things contemplated by the forward-looking statementswill not occur.
Although our management believes that the expectations represented by suchforward-looking statements are reasonable, there is significant risk that theforward-looking statements may not be achieved, and the underlying assumptionsthereto will not prove to be accurate. Forward-looking statements in this newsrelease include, but are not limited to, statements concerning ourexpectations for: interim 4-week data from a Phase II viral kineticscombination study of celgosivir now being anticipated in November.
With respect to the forward-looking statements contained in this newsrelease, we have made numerous assumptions regarding, among other things: thecontract organization's ability to complete the sample analysis and thecompletion of the interim 4-week data analysis being in November 2007.
Actual results or events could differ materially from the plans,intentions and expectations expressed or implied in any forward-lookingstatements, including the underlying assumptions thereto, as a result ofnumerous risks, uncertainties and other factors including: dependence oncorporate collaborations; uncertainties related to early stage of technologyand product development; and potential delays. Certain of these factors andother factors are described in detail in the Company's Annual Information Formand Annual Report on Form 20-F for and other filings with the Canadiansecurities regulatory authorities and the U.S. Securities & ExchangeCommission.
Forward-looking statements are based on our current expectations andMIGENIX assumes no obligations to update such information to reflect laterevents or developments.
CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233,email@example.com; Dian Griesel, Ph.D., Investor
You May Also Like